A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants
Status:
Recruiting
Trial end date:
2022-01-22
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to look at the amount of the study drug, lebrikizumab, that
gets into the blood stream and how long it takes the body to get rid of lebrikizumab
(LY3650150) when given using either a pre-filled autoinjector (AI) or a pre-filled syringe
with needle safety device (PFS-NSD). The safety and tolerability of lebrikizumab will also be
evaluated. The study will last up to 102 days.